DONATE

Search Results for:

Learning from the experts

cedeIBEC group leader Samuel Sanchez was one of the experts and professionals invited to take part in CEDE’s “Talento en Crecimiento” event at the Palacio de Exposiciones y Congresos in A Coruña at the beginning of the month.

He took to the stage with some of the most influential business leaders, entrepreneurs and experts in the country, including Francisco Reynes, CEO of Abertis, Juan Urdiales, co-founder of Jobandtalent, and Maria Salamero, Director of Innovation and Knowledge at Agbar, all of which were there to give the 500 young attendees advice on career advancement, personal branding, mobility and employability.

PhD Thesis Defense: Ana Guaman

“Multivariate Signal Processing for Quantitative and Qualitative analysis of Ion Mobility Spectrometry applied to Biomedical and Food Applications”

PhD Thesis Defense: Ana Guaman

“Multivariate Signal Processing for Quantitative and Qualitative analysis of Ion Mobility Spectrometry applied to Biomedical and Food Applications”

Severo Ochoa centres meet in La Palma

100xcienciaThe 100XCIENCIA “Communicating frontier science” forum took place last week in Santa Cruz de La Palma. IBEC Director Josep Samitier was one of the twenty directors that presented their Severo Ochoa Centres of Excellence to the assembled science communicators and journalists, including the New York Times’ Kenneth Chang.

The three-day unprecedented event also included round tables during which the directors, journalists and other professionals including European Commission representatives could discuss topics such as science policy, science in the media, and the impact of outreach activities.

Possible new treatment for bladder cancer using a mycobacterium

Collaborators at the UAB and IBEC have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

Mycobacteria are the only bacteria used in cancer treatment. The administration of the bacterium Mycobacterium bovis (BCG) is the current treatment for superficial bladder cancer, and is inserted directly into the bladder through a catheter. BCG prevents new tumours from appearing, but despite its efficacy it has many adverse side effects, the most serious being BCG infections that need to be treated with antituberculous drugs.